Skye Bioscience (Skye Bioscience) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Debt-to-Equity?

Skye Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.69 Mil. Skye Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.15 Mil. Skye Bioscience's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $78.88 Mil. Skye Bioscience's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Skye Bioscience's Debt-to-Equity or its related term are showing as below:

SKYE' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.39 Med: -0.05 Max: 3.32
Current: 0.06

During the past 12 years, the highest Debt-to-Equity Ratio of Skye Bioscience was 3.32. The lowest was -8.39. And the median was -0.05.

SKYE's Debt-to-Equity is ranked better than
69.84% of 1081 companies
in the Biotechnology industry
Industry Median: 0.15 vs SKYE: 0.06

Skye Bioscience Debt-to-Equity Historical Data

The historical data trend for Skye Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Debt-to-Equity Chart

Skye Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.71

3.32

0.36

-0.66

-2.17

Skye Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-0.05	-0.05	2.61	-2.17	0.06

Competitive Comparison of Skye Bioscience's Debt-to-Equity

For the Biotechnology subindustry, Skye Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skye Bioscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Debt-to-Equity falls into.

Skye Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Skye Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.444	+	0.171)	/	-2.132
	=	-2.16

Skye Bioscience's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.685	+	0.151)	/	78.883
	=	0.06

Skye Bioscience (NAS:SKYE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Skye Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience (Skye Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130

Website

https://www.skyebioscience.com

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.

Executives

Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman	10 percent owner	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych	director	1001 17TH ST, SAN FRANCISCO CA 94107